<DOC>
	<DOCNO>NCT01869959</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability LY2405319 . It give daily injection skin participant type 2 diabetes mellitus ( T2DM ) 28 day . This study determine long drug stay body affect blood sugar level . After screen , study last 2 month participant . Participants continue prestudy regimen diet exercise alone combination metformin .</brief_summary>
	<brief_title>A Study LY2405319 Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Have diagnosis T2DM . Are diet exercise diet , exercise , metformin ( stable dose least 1000 mg/day least 60 day ) regimen . Have glycosylated hemoglobin A1c ( HbA1c ) value 7.0 % 10.0 % , inclusive , metformin additional oral antidiabetic medication ( OAM ) HbA1c value 6.5 % 9.5 % , inclusive . Participants another OAM addition metformin therapy may randomize remove treatment OAM ≥14 day prior study drug administration fast blood glucose ≥145 mg per deciliter ( mg/dL ) ≤270 mg/dL . Are females childbearing potential due surgical sterilization postmenopausal . Have body mass index ( BMI ) ≥25 ≤40 . Have clinical laboratory test result within normal reference range population . Use insulin , thiazolidinediones ( TZDs ) , dipeptidyl peptidase ( DPP ) IV inhibitor , exenatide 3 month prior screen . Have 1 episode severe hypoglycemia require assistance another person administer resuscitative action within 6 month prior entry study currently diagnose hypoglycemia unawareness . Have 2 emergency room visit hospitalization due poor glucose control past 6 month . Have abnormality electrocardiogram ( ECG ) , opinion investigator , impair ability measure QT ( correct QC [ QTc ] [ Bazett 's correction ] interval &gt; 450 millisecond [ msec ] men &gt; 470 msec woman PR interval &gt; 220 msec specifically exclude ) conduction abnormality may confound QTc analysis . Have personal family history long QT syndrome , family history sudden death , personal history unexplained syncope within last year ; use prescription overthecounter medication know prolong QT QTc interval . Have diastolic blood pressure ( DBP ) ≥95 millimeter mercury ( mm Hg ) and/or systolic blood pressure ( SBP ) ≥160 mm Hg . Have active untreated malignancy remission clinically significant malignancy &lt; 5 year . Have history transplant organ . Evidence significant active , uncontrolled endocrine autoimmune abnormality , judge investigator , screen . Have history human immunodeficiency virus ( HIV ) . Have know allergy yeast yeast protein , history anaphylaxis bronchospasm , atopic dermatitis chronic urticaria . Have condition ( include know drug alcohol abuse psychiatric disorder within last 6 month ) may preclude participant follow complete protocol . Have significant history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine ( include pancreatitis ) , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data . Are woman breastfeed . Have significant change weight , define gain loss least 4 kilogram ( kg ) ( 9 pound ) 90 day prior randomization . Have take 30 day prior randomization , medication , herbal product , nutritional supplement affect adipose mass distribution energy balance . Are receive chronic ( &gt; 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 4 week immediately prior second screening appointment . Have current recent ( within past 3 month ) use gemfibrozil fenofibrate , niacin , ezetimibe , bile acid binding resin ( example , cholestyramines ) . Stable statin therapy ≥3 month allow . Are currently take central nervous system ( CNS ) stimulant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>